<DOC>
	<DOCNO>NCT00638248</DOCNO>
	<brief_summary>The purpose study explore trend safety efficacy , find optimal dose subsequent phase III trial . The decision initiate phase III trial depend safety ( incidence symptomatic intracranial hemorrhage ) efficacy ( reperfusion measure MRI correlate clinical outcome ) profile . The safety ( incidence symptomatic intracranial haemorrhage ) efficacy ( reperfusion measure MRI correlate clinical outcome ) profile gain study basis plan phase III .</brief_summary>
	<brief_title>Dose Escalation Desmoteplase Acute Ischemic Stroke ( DEDAS )</brief_title>
	<detailed_description>Acute stroke third leading cause mortality develop country major medical cause disability adult . The outcome improve early treatment thrombolysis . Alteplase ( r-tPA ) approve thrombolytic drug indication acute ischemic stroke . However , use alteplase currently restrict need administer within 3 hour symptom onset . As risk transform cerebral infarct haemorrhage probably rise time elapsed increase , thrombolytic drug carry low risk haemorrhage alteplase may offer wide time-to-treatment window improve safety profile . Desmoteplase ( DSPA ) high fibrin specificity , lack neurotoxicity , potential neuroprotective effect , non-activation ÃŸ-amyloid , long terminal half-life may account improved safety efficacy profile within first 9 hour onset symptom .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Salivary plasminogen activator alpha 1 , Desmodus rotundus</mesh_term>
	<criteria>score 4 20 National Institute Health Stroke Scale ( NIHSS ) show perfusiondiffusion mismatch MRI 20 % enrolment within 3 h 9 h time window symptom onset . 1885 year age Participation interventional trial previous 30 day . Women childbearing age . Any history intracranial hemorrhage , subarachnoid hemorrhage , neoplasm , arteriovenous malformation aneurysm . Conditions , accord judgment investigator , might impose additional risk individual stroke patient receiving study medication ( applied patient plateletfunction inhibitor well ) . MRI exclusion criterion : Evidence ICH , Evidence SAH , Signs extensive early infarction DWI assess evidence involvement &gt; 1/3 middle cerebral artery ( MCA ) territory . No perfusion deficit , Internal carotid artery ( ICA ) occlusion ipsilateral stroke lesion without additional ipsilateral MCA , anterior cerebral artery ( ACA ) posterior cerebral artery ( PCA ) occlusion . Any intracranial pathology would interfere MRI assessment acute ischemic stroke .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Acute ischemic stroke</keyword>
</DOC>